Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Study ID
- NCT05613296
- Status
- Completed
Conditions
- Chronic ITP
- ITP - Immune Thrombocytopenia
- Refractory ITP
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fostamatinib — DRUGPatients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
Study Details
This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.
Key Dates
- Start date
- May 5, 2023
- Status verified
- Apr 2025
- Primary completion
- May 31, 2024
- Completion
- May 31, 2024
Study Design
- Enrollment
- 95 participants (actual)
Arms
- Arm: Study groupAll patients being observed during the study duration.
Primary Outcome Measure
Number of ITP patients who receive Fostamatinib [ Time Frame: 6 months ]